No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 1094-1100

  Kiechl, Stefan ^a,d   Willeit, Johann ^a   Bonora, Enzo ^b   Schwarz, Siegfried ^a   Xu, Qingbo ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF VERONA   (Italy)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Aging; Atherosclerosis; Dehydroepiandrosterone; Insulin resistance; Risk factors

Indexed keywords

PRASTERONE SULFATE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG EFFECT; FEMALE; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE AGGREGATION;

EID: 0034113707     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.1094     Document Type: Article

References (53)

1. Nafziger AN, Herrington DM, Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev. 1991;13:267-293.
2. Schwartz AG, Fairman DK, Paschko LL. The biological significance of dehydroepiandrosterone. In: Kalimi MN, Regelson W, eds. The Biologic Role of Dehydroepiandrosterone (DHEA). Berlin, Germany: Walter De Gruyter 38 Co; 1990:7-12.
3. Kask E. 17-Ketosteroids and arteriosclerosis. Angiology. 1959;10: 358-368.
4. Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: the 'missing link' between hyperinsulinemia and atherosclerosis? FASEB J. 1992;6:3073-3075.
5. Ben-David M, Dikstein S, Bismuth G, Sulman FG. Antihypercholesterolemic effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med. 1967;125:1136-1140.
6. LaCroix AZ, Yano K, Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation. 1992;86:1529-1535.
7. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 1990;16:862-870.
8. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci. 1995;774:271-280.
9. Barrett-Connor E, Khaw KT. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med. 1987;317:711. Letter.
10. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women: the Rancho Bernardo Study. Circulation. 1995;91:1757-1760.
11. Barrett-Connor E, Khaw K-T, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519-1524.
12. Zumoff B, Troxler RG, O'Connor J, Rosenfeld RS, Kream J, Levin J, Hickman JR, Sloan AM, Walker W, Cook RL, Fukushima DK. Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis. 1982;2:58-67.
13. Feldman HA, Johannes CB, McKinlay JB, Longcope C. Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. Ann Epidemiol. 1998;8:217-228.
14. Mitchell LE, Sprecher DL, Boreki JB, Rice T, Laskarezewski PM, Rao DC. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation. 1994;89:89-93.
15. Hautanen A, Mänttäri M, Koskinen P. Dehydroepiandrosterone sulfate as a coronary risk factor in the Helsinki Heart Study. Circulation. 1982; 82(suppl III):III-468. Abstract.
16. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart. 1998;80:334-337.
17. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol. 1994;140: 870-875.
18. Willeit J, Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis: a population-based study. Arterioscler Thromb. 1993;13:661-668.
19. Kiechl S, Willeit J. The natural course of atherosclerosis, II: vascular remodeling. Arterioscler Thromb Vasc Biol. 1999;19:1491-1498.
20. Kiechl S, Willeit J. The natural course of atherosclerosis, I: incidence and progression. Arterioscler Thromb Vasc Biol. 1999;19:1484-1490.
21. World Health Organization. Arterial Hypertension: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1978:9-17. Technical Report Series, No. 628.
22. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-1649.
23. IHD register. Report of the Fifth Working Group. Copenhagen, Denmark: World Health Organization; 1971.
24. Walker A, Robins M, Weinfeld F. The National Survey of Stroke: clinical findings. Stroke. 1981;12(suppl I):I-13-I-49.
25. Clauss A. Gerrinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
26. Orentreich N, Brind JL, Rizer RL. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-555.
27. Schwarz S, Pohl P. Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individuals with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology. 1992; 55:174-182.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
29. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1988.
30. Cox DR, Oakes D. Analysis of Survival Data. London, UK: Chapman & Hall; 1984.
31. Johannes CB, Stellato RK, Feldman HA, Longcope C, McKinlay JB. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. J Clin Epidemiol. 1999; 52:95-103.
32. Salvini S, Stampfer MJ, Barbieri RL, Hennekens CH. Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. J Clin Endocrinol Metab. 1992;74:139-143.
33. Khaw KT, Tazuke S, Barrett-Connor E. Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med. 1988;318: 1705-1709.
34. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-555.
35. Andò S, Rubens R, Rottiers R. Androgen plasma levels in male diabetics. J Endocrinol Invest. 1984;7:21-24.
36. Yamaguchi Y, Tanaka S, Yamakawa T, Kimura M, Ukawa K, Yamada Y, Ishihara M, Sekihara H. Reduced serum dehydroepiandrosterone levels in diabetic patients with hyperinsulinaemia. Clin Endocrinol. 1998;49: 377-383.
37. Abbasi A, Duthie EH Jr, Sheldahl L, Wilson C, Sasse E, Rudman I, Mattson DE. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. J Am Geriatr Soc. 1998;46:263-273.
38. Straub RH, Vogl D, Gross V, Lang B, Scholmerich J, Andus T. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol. 1998;93:2197-2202.
39. Parker LN, Levin ER, Lifrak ET. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab. 1985;60:947-952.
40. Nestler JE, McClanahan MA, Clore JN, Blackward WG. Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Metab. 1992;74: 362-367.
41. Mukasa K, Kanesiro M, Aoki K, Okamura J, Saito T, Satoh S, Sekihara H. Dehydroepiandrosterone (DHEA) ameliorates the insulin sensitivity in older rats. J Steroid Biochem Mol Biol. 1998;67:355-358.
42. Schriock ED, Buffington CK, Hubert GD, Kurtz BR, Kitabchi AE, Buster JE, Givens JR. Divergent correlation of circulatory dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 1988;66:1329-1331.
43. Haffner SM, Valdez RA, Mykkänen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 1994;43:599-603.
44. Denti L, Pasolini G, Sanfelici L, Ablondi F, Freddi M, Benedetti R, Valenti G. Effects of aging on dehydroepiandrosterone sulfate in relation to fasting insulin levels and body composition assessed by bioimpedance analysis. Metabolism. 1997;46:826-832.
45. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 1993;87:261-269.
46. Arad Y, Badimon JO, Badimon L, Hembrec W, Ginsberg HN. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis. 1989;9: 159-166.
47. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone: a study in the hypercholesterolemic New Zealand White rabbit with aortic intimal injury. J Clin Invest. 1988;82:712-720.
48. Yamaji T, Ibayashi H. Plasma dehydroepiandrosterone sulfate in normal and pathological conditions. J Clin Endocrinol Metab. 1969;29:273-278.
49. Rudman D, Shetty KR, Mattson DE. Plasma dehydroepiandrosterone sulfate in nursing home men. J Am Geriatr Soc. 1990;38:421-427.
50. Lissoni P, Rovelli F, Giani L, Mandala M, Meregalli S, Barni S, Confalonieri G, Bonfanti A. Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease. Int J Biol Markers. 1998;13:154-157.
51. Watson RR, Huls A, Araghinikuam M, Chung S. Dehydroepiandrosterone and diseases of aging. Drugs Aging. 1996:9;274-291.
52. Kalmijn S, Launer LJ, Stolk RP, de Jong FH, Pols HA, Hofman A, Breteler MM, Lamberts SW. A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab. 1998;83:3487-3492.
53. Skolnick AA. Scientific verdict still out on DHEA. JAMA. 1996;276: 1365-1367.